Showing 18,581 - 18,600 results of 48,330 for search '(( 50 ((nn decrease) OR (((mean decrease) OR (a decrease)))) ) OR ( 12 we decrease ))', query time: 1.34s Refine Results
  1. 18581

    Effect of implementing care protocols on acute ischemic stroke outcomes: a systematic review by Karina Fonseca de Souza Leite (15475307)

    Published 2023
    “…A decrease in mortality was mentioned in 3 (25.0%) articles out of 12 that evaluated this outcome. …”
  2. 18582
  3. 18583
  4. 18584
  5. 18585
  6. 18586
  7. 18587

    Deforestation Impacts on Bat Functional Diversity in Tropical Landscapes by Rodrigo García-Morales (3386141)

    Published 2016
    “…We captured 906 bats (Phyllostomidae and Mormoopidae), including 10 genera and 12 species. …”
  8. 18588

    Table_1_ATP-citrate lyase inhibitor improves ectopic lipid accumulation in the kidney in a db/db mouse model.docx by Zishun Zhan (14233709)

    Published 2022
    “…We reported that BMS-303141 administration could decrease the levels of serum lipid and renal lipogenic enzymes acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), HMG-CoA reductase (HMGCR), and diminish renal ELA in db/db mice. …”
  9. 18589

    Image_1_ATP-citrate lyase inhibitor improves ectopic lipid accumulation in the kidney in a db/db mouse model.tif by Zishun Zhan (14233709)

    Published 2022
    “…We reported that BMS-303141 administration could decrease the levels of serum lipid and renal lipogenic enzymes acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), HMG-CoA reductase (HMGCR), and diminish renal ELA in db/db mice. …”
  10. 18590

    Image_2_ATP-citrate lyase inhibitor improves ectopic lipid accumulation in the kidney in a db/db mouse model.tif by Zishun Zhan (14233709)

    Published 2022
    “…We reported that BMS-303141 administration could decrease the levels of serum lipid and renal lipogenic enzymes acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), HMG-CoA reductase (HMGCR), and diminish renal ELA in db/db mice. …”
  11. 18591

    The morphogenesis and development of VM dopaminergic neurons is disturbed in <i>Dkk1<sup><b>−/−</b></sup></i> embryos. by Diogo Ribeiro (230483)

    Published 2011
    “…(B) Immunohistochemistry for TH in midbrain sections of <i>Dkk1<sup>−/−</sup></i> embryos revealed a decrease of aberrantly distributed dopaminergic neurons (upper panels) or an almost absence of dopaminergic neurons (bottom panels). …”
  12. 18592

    Emodin suppresses HG-induced cFLIP generation but not repressing its activation and increasing degration. by Junjie Gao (545578)

    Published 2014
    “…<p>(<b>a, b</b>) MCs were cultured in HG media and treated with 50 μM emodin for indicated times. …”
  13. 18593

    Table_1_Effect and Safety of Adding Metformin to Insulin Therapy in Treating Adolescents With Type 1 Diabetes Mellitus: An Updated Meta-Analysis of 10 Randomized Controlled Trials.... by Ying Liu (18461)

    Published 2022
    “…Results suggested that metformin significantly decreased the HbA1c level at 12 months (mean difference [MD])=-0.50, 95% confidence interval [CI]=-0.61 to -0.39, P < 0.01); BMI (kg/m<sup>2</sup>) at 3 months (MD=-1.05, 95%CI=-2.05 to -0.05, P=0.04); BMI z-score at 6 months (MD=-0.10, 95%CI=-0.14 to -0.06, P<0.01); and TIDD at 3 (MD=-0.13, 95%CI=-0.20 to -0.06, P<0.01), 6 (MD=-0.18, 95%CI=-0.25 to -0.11, P<0.01), and 12 (MD=-0.42, 95%CI=-0.49 to -0.35, P<0.01) months but significantly increased the risk of hypoglycemia events (risk ratio [RR]=3.13, 95%CI=1.05 to 9.32, P=0.04) and GIAEs (RR=1.64, 95%CI=1.28 to 2.10, P<0.01). …”
  14. 18594

    Table_2_Effect and Safety of Adding Metformin to Insulin Therapy in Treating Adolescents With Type 1 Diabetes Mellitus: An Updated Meta-Analysis of 10 Randomized Controlled Trials.... by Ying Liu (18461)

    Published 2022
    “…Results suggested that metformin significantly decreased the HbA1c level at 12 months (mean difference [MD])=-0.50, 95% confidence interval [CI]=-0.61 to -0.39, P < 0.01); BMI (kg/m<sup>2</sup>) at 3 months (MD=-1.05, 95%CI=-2.05 to -0.05, P=0.04); BMI z-score at 6 months (MD=-0.10, 95%CI=-0.14 to -0.06, P<0.01); and TIDD at 3 (MD=-0.13, 95%CI=-0.20 to -0.06, P<0.01), 6 (MD=-0.18, 95%CI=-0.25 to -0.11, P<0.01), and 12 (MD=-0.42, 95%CI=-0.49 to -0.35, P<0.01) months but significantly increased the risk of hypoglycemia events (risk ratio [RR]=3.13, 95%CI=1.05 to 9.32, P=0.04) and GIAEs (RR=1.64, 95%CI=1.28 to 2.10, P<0.01). …”
  15. 18595

    <b>Effect of Weight Loss on Skeletal Muscle Bioactive Lipids in People with Obesity and Type 2 Diabetes</b> by Max C. Petersen (19589639)

    Published 2024
    “…Here, we evaluated whether weight loss-induced improvements in insulin sensitivity were associated with changes in muscle sn-1,2-DAG and ceramide content in people with obesity and type 2 diabetes. …”
  16. 18596
  17. 18597
  18. 18598
  19. 18599

    <i>N. meningitidis</i> infection of HBMEC causes degradation of occludin. by Alexandra Schubert-Unkmeir (154787)

    Published 2010
    “…A weak specific occludin fragment with an apparent molecular mass of 50–kDa is generated during infection at 24 h p.i. …”
  20. 18600